HK184896A - Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine - Google Patents

Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine Download PDF

Info

Publication number
HK184896A
HK184896A HK184896A HK184896A HK184896A HK 184896 A HK184896 A HK 184896A HK 184896 A HK184896 A HK 184896A HK 184896 A HK184896 A HK 184896A HK 184896 A HK184896 A HK 184896A
Authority
HK
Hong Kong
Prior art keywords
tablet
composition
hydrophilic polymer
pseudoephedrine
loratadine
Prior art date
Application number
HK184896A
Other languages
English (en)
French (fr)
Inventor
P Cho Wing-Kee
A Vadino Winston
A Chaundry Imtiaz
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HK184896A publication Critical patent/HK184896A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

  1. Pharmazeutische Zusammensetzung zur verzögerten Freisetzung, welche eine überzogene Tablette umfaßt, in welcher der Tablettenüberzug eine antihistaminisch wirksame Menge Loratadine oder 8-Chlor-6,11-dihydro-11-(4-piperidyliden)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin und ein hydrophiles Polymer umfaßt, und der Tablettenkern eine analgetisch wirksame Menge Ibuprofen, eine kongestionsvermindernd wirksame Menge Pseudoephedrin oder ein pharmazeutisch annehmbares Salz desselben und ein quellbares hydrophiles Polymer umfaßt und worin der Tablettenüberzug und der Tablettenkern weiter pharmazeutisch annehmbare Arzneimittelhilfsstoffe enthalten.
  2. Zusammensetzung des Anspruchs 1, bei welcher der Tablettenkern 10 bis 55% des Gewichts der überzogenen Tablette Ibuprofen, 3 bis 25% des Gewichts der überzogenen Tablette Pseudoephedrin oder ein pharmazeutisch annehmbares Salz desselben und 5 bis 15% des Gewichts des Tablettenkerns eines hydrophilen Polymers umfaßt.
  3. Zusammensetzung des Anspruchs 2, bei welcher der Tablettenkern weiter 10 bis 20% Füllstoff, 0 bis 5% Antihaftmittel, 0,25 bis 5% Gleitmittel und 0,5 bis 3% Bindemittel umfaßt.
  4. Zusammensetzung des Anspruchs 3, bei welcher das hydrophile Polymer ein Celluloseether ist, welcher aus Methylcellulose, Hydroxypropylcellulose, Hydroxymethylcellulose, Hydroxyethylcellulose, Carboxymethylcellulose, Carboxyethylcellulose und deren Gemischen ausgewählt ist, und der Füllstoff dibasisches Calciumphosphat oder das Dihydrat desselben, mikrokristalline Cellulose oder Lactose ist, das Antihaftmittel Siliziumdioxid oder Talk ist, das Gleitmittel Magnesiumstearat oder Stearinsäure ist und das Bindemittel Povidone oder Maisstärke ist.
  5. Zusammensetzung des Anspruchs 3, bei welcher das hydrophile Polymer Hydroxypropylmethylcellulose USP 2910 oder Hydroxypropylmethylcellulose USP 2208 mit einer Viskosität von 100000 cPs in einer 2%igen wäßrigen Lösung ist, der Füllstoff mikrokristalline Cellulose ist, das Gleitmittel Magnesiumstearat ist und das Bindemittel Povidone ist.
  6. Zusammensetzung des Anspruchs 1, bei welcher der Tablettenkern 120 mg Pseudoephedrinsulfat, 555 mg Ibuprofen 90%, 100 mg Hydroxypropylmethylcellulose USP 2208 mit einer Viskosität von 100000 cPs in einer 2%igen wäßrigen Lösung, 10 mg Povidone, 154 mg mikrokristalline Cellulose und 5 mg Magnesiumstearat umfaßt und bei welcher der Tablettenüberzug 5 mg Loratadine und 10 mg eines 5:1-Gemischs von Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 6 cPs in einer 2%igen wäßrigen Lösung und Polyethylenglykol mit einem Molekulargewicht von 300-6000 umfaßt.
  7. Zusammensetzung des Anspruchs 1, bei welcher der Tablettenkern 120 mg Pseudoephedrinsulfat, 555 mg Ibuprofen 90%, 150 mg Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 4000 cPs in einer 2%igen wäßrigen Lösung, 75 mg Povidone, 148,5 mg mikrokristalline Cellulose, 14 mg Siliziumdioxid und 5 mg Magnesiumstearat umfaßt und in welcher der Tablettenüberzug 5 mg Loratadine und 10 mg eines 5:1-Gemischs von Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 6 cPs in einer 2%igen wäßrigen Lösung und Polyethylenglykol mit einem Molekulargewicht von 300-6000 umfaßt.
  8. Pharmazeutische Zusammensetzung zur verzögerten Freisetzung, welche eine überzogene Tablette umfaßt, bei welcher der Tablettenüberzug eine antihistaminisch wirksame Menge Loratadine oder 8-Chlor-6,11-dihydro-11-(4-piperidyliden)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin und ein hydrophiles Polymer umfaßt, und der Tablettenkern eine analgetisch wirksame Menge Acetaminophen, eine kongestionsvermindernd wirksame Menge Pseudoephedrin oder ein pharmazeutisch annehmbares Salz desselben und ein quellbares hydrophiles Polymer umfaßt und worin der Tablettenüberzug und der Tablettenkern weiter pharmazeutisch annehmbare Arzneimittelhilfsstoffe enthalten.
  9. Zusammensetzung des Anspruchs 8, bei welcher der Tablettenkern 10 bis 65% des Gewichts der überzogenen Tablette Acetaminophen, 3 bis 35% des Gewichts der überzogenen Tablette Pseudoephedrin oder ein pharmazeutisch annehmbares Salz desselben und 5 bis 15% des Gewichts des Tablettenkerns eines hydrophilen Polymers umfaßt.
  10. Zusammensetzung des Anspruchs 9, bei welcher der Tablettenkern weiter 10 bis 20% Füllstoff, 0 bis 5% Antihaftmittel, 0,25 bis 5% Gleitmittel und 0 bis 3% Bindemittel umfaßt.
  11. Zusammensetzung des Anspruchs 9, bei welcher das hydrophile Polymer ein Celluloseether ist, welcher aus Methylcellulose, Hydroxypropylcellulose, Hydroxymethylcellulose, Hydroxyethylcellulose, Carboxymethylcellulose, Carboxyethylcellulose und deren Gemischen ausgewählt ist, und der Füllstoff dibasisches Calciumphosphat oder das Dihydrat desselben, mikrokristalline Cellulose oder Lactose ist und das Gleitmittel Magnesiumstearat oder Stearinsäure ist.
  12. Zusammensetzung des Anspruchs 11, bei welcher das hydrophile Polymer Hydroxypropylmethylcellulose USP 2910 oder Hydroxypropylmethylcellulose USP 2208 mit einer Viskosität von 100000 cPs in einer 2%igen wäßrigen Lösung ist, der Füllstoff dibasisches Calciumphosphatdihydrat ist und das Gleitmittel Magnesiumstearat und Stearinsäure ist.
  13. Zusammensetzung des Anspruchs 8, bei welcher der Tablettenkern 60 mg Pseudoephedrinsulfat, 555 mg Acetaminophen 90%, 48 mg Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 4000 cPs in einer 2%igen wäßrigen Lösung, 98 mg dibasisches Calciumphosphatdihydrat, 10 mg Stearinsäure und 4 mg Magnesiumstearat umfaßt und bei welcher der Tablettenüberzug 2,5 mg Loratadine und 5 mg eines 5:1-Gemischs von Hydroxypropylmethylcellulose USP 2910 mit einer Viskosität von 6 cPs in einer 2%igen wäßrigen Lösung und Polyethylenglykol mit einem Molekulargewicht von 300-6000 umfaßt.
HK184896A 1989-05-03 1996-10-03 Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine HK184896A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/346,687 US4990535A (en) 1989-05-03 1989-05-03 Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine

Publications (1)

Publication Number Publication Date
HK184896A true HK184896A (en) 1996-10-11

Family

ID=23360584

Family Applications (1)

Application Number Title Priority Date Filing Date
HK184896A HK184896A (en) 1989-05-03 1996-10-03 Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine

Country Status (13)

Country Link
US (2) US4990535A (de)
EP (2) EP0396404B1 (de)
JP (1) JPH066536B2 (de)
KR (1) KR940011246B1 (de)
AT (1) ATE101517T1 (de)
AU (1) AU628986B2 (de)
CA (1) CA2054752C (de)
DE (1) DE69006628T2 (de)
DK (1) DK0396404T3 (de)
ES (1) ES2062355T3 (de)
HK (1) HK184896A (de)
MX (1) MX9203278A (de)
WO (1) WO1990013295A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1252692A (en) * 1991-03-04 1992-10-06 Warner-Lambert Company Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms
JPH069382A (ja) * 1992-04-17 1994-01-18 Takeda Chem Ind Ltd 安定化された固型製剤およびその製造方法
ZA933725B (en) * 1992-05-28 1993-12-15 Elan Corp Plc Tablet formulation
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
JPH08506808A (ja) * 1992-12-21 1996-07-23 ザ、プロクター、エンド、ギャンブル、カンパニー 呼吸障害治療用組成物の製造における鎮痛剤ｓ（＋）対掌体の利用
CN1071570C (zh) * 1993-06-14 2001-09-26 詹森药业有限公司 阿司咪唑和假麻黄碱的缓释薄膜包衣片
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
EP0812195B1 (de) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Arzneizubereitungen für piperidinalkanolderivate
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
ES2248847T3 (es) * 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
EP0811374A1 (de) 1996-05-29 1997-12-10 Pfizer Inc. Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
EP0941091A1 (de) * 1996-10-31 1999-09-15 Schering Corporation Loratadin und dekongestirum enthaltende zusammensetzung zur behandlung von asthma
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
AU776837B2 (en) * 1997-02-07 2004-09-23 Sunovion Pharmaceuticals Inc. Lactose-free non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
NZ501248A (en) * 1997-08-26 2001-06-29 Aventis Pharma Inc Pharmaceutical composition for combination of piperidinoalkanol-decongestant
JP3224379B1 (ja) * 1998-07-10 2001-10-29 シェーリング コーポレイション ８−クロロ−６，１１−ジヒドロ−１１−（４−ピペリジリデン）−５Ｈ−ベンゾ［５，６］シクロヘプタ［１，２−ｂ］ピリジンの経口用組成物
AU6018899A (en) * 1998-09-10 2000-04-03 Schering Corporation Antihistamines for treating non-infective sinusitis or otitis media
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
KR100505899B1 (ko) * 1999-02-23 2005-08-01 주식회사유한양행 로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
US6114346A (en) 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045676A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US6613357B2 (en) * 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
DE10003757A1 (de) * 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
JP5592042B2 (ja) * 2000-04-14 2014-09-17 ジェイ−メド ファーマシューティカルズ，インコーポレーティッド 鼻炎治療のための単一投与抗ヒスタミン薬／鬱血除去薬製剤
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
US20020094345A1 (en) 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CA2725833A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
EP1353695A2 (de) * 2001-01-26 2003-10-22 Schering Corporation Kombinationen von einem hemmer der sterol-absorption und nicotinsäure zur behandlung von kardiovaskulären indikationen
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
RS20100015A (sr) * 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
IL156488A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
PT1355644E (pt) * 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
ATE369851T1 (de) * 2001-01-26 2007-09-15 Schering Corp Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
US20040156900A1 (en) * 2001-04-10 2004-08-12 Shanghvi Dilip Shantilal Time pulsed release composition
DE60216275T2 (de) * 2001-05-25 2007-06-21 Schering Corp. Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
WO2003000264A1 (en) * 2001-06-20 2003-01-03 Schering Corporation Antihistamines for the treatment of nasal congestion and nasal obstruction
US9820982B2 (en) * 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
CN101785772A (zh) * 2001-09-21 2010-07-28 先灵公司 使用甾醇吸收抑制剂治疗或预防脉管炎的方法
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
EP1429756B1 (de) * 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
CA2447984A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell with different shapes
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
JP2006508188A (ja) * 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
CL2003002653A1 (es) * 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
US20040142903A1 (en) * 2003-01-16 2004-07-22 Par Pharmaceutical Inc. Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756756A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
EP1663165B1 (de) * 2003-07-28 2008-12-03 Mallinckrodt, Inc. Verbesserte stearat-zusammensetzung und herstellungsverfahren dafür
US8246986B2 (en) 2003-09-26 2012-08-21 Alza Corporation Drug coating providing high drug loading
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US8188067B2 (en) * 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
CN104161736A (zh) 2006-06-01 2014-11-26 Msd消费保健品公司 包含去氧肾上腺素的缓释药物制剂
CA2653950A1 (en) * 2006-06-01 2007-12-13 Schering Corporation Phenylephrine pulsed release formulations and pharmaceutical compositions
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
WO2009089134A1 (en) 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
US20130115250A1 (en) * 2009-05-13 2013-05-09 Wyeth Llc Burst Drug Release Compositions
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
JP5752578B2 (ja) * 2011-12-09 2015-07-22 ジェイ−メド ファーマシューティカルズ，インコーポレーティッド 鼻炎治療のための単一投与抗ヒスタミン薬／鬱血除去薬製剤
EP2727592A1 (de) * 2012-11-05 2014-05-07 Kücükgüzel, Sükriye Güniz Kombination aus Desloratadin und Paracetamol
AU2014369916A1 (en) 2013-12-24 2016-06-16 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
WO2017066619A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
CA3124579C (en) 2020-07-15 2026-03-31 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
PY2162539A (es) 2020-07-30 2022-02-15 Faes Farma Sa Sistema de administración de fármacos descongestivos y bilastina

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
JPS61501205A (ja) 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション ８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4871733A (en) * 1984-04-09 1989-10-03 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
FR2576213B1 (fr) * 1985-01-21 1989-02-24 Cortial Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions

Also Published As

Publication number Publication date
US5100675A (en) 1992-03-31
AU628986B2 (en) 1992-09-24
CA2054752A1 (en) 1990-11-04
AU5664890A (en) 1990-11-29
KR920700033A (ko) 1992-02-19
JPH04501425A (ja) 1992-03-12
EP0471009A1 (de) 1992-02-19
DE69006628D1 (de) 1994-03-24
CA2054752C (en) 1996-12-31
EP0396404A1 (de) 1990-11-07
DE69006628T2 (de) 1994-05-26
DK0396404T3 (da) 1994-03-14
ATE101517T1 (de) 1994-03-15
EP0396404B1 (de) 1994-02-16
ES2062355T3 (es) 1994-12-16
WO1990013295A1 (en) 1990-11-15
US4990535A (en) 1991-02-05
MX9203278A (es) 1992-07-01
JPH066536B2 (ja) 1994-01-26
KR940011246B1 (ko) 1994-12-03

Similar Documents

Publication Publication Date Title
EP0396404B1 (de) Pharmazeutische Zusammensetzung, enthaltend Loratadin, Ibuprofen und Pseudoephedrin
US4601894A (en) Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
KR101234940B1 (ko) 안정한 서방출형의 경구 투여용 조성물
AU676229B2 (en) Stable extended release oral dosage composition
EP0103636B1 (de) Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler störungen
US4829064A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
DE69836424T2 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
US4975426A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
AU703242B2 (en) Film coated tablet of paracetamol and domperidone
KR20010075021A (ko) 불법적 용도로서 부적합한 교감신경흥분성 아민 염을포함하는 조성물
EP0348683A1 (de) Ibuprofen in Kombination mit einem Piperidinylalkanolantihistaminikum enthaltenden Arzneimittel
NZ244564A (en) Pharmaceutical composition for treating pain of chronic medical conditions comprising ibuprofen and codeine in a ratio range of 15-25:1
US4657757A (en) Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
JP3018160B2 (ja) 月経困難症及び／又は月経前症候群の軽減用薬剤
GB2281205A (en) Oral opioid analgesic
WO2007143163A2 (en) Pharmaceutical compositions for sustained release of phenyephrine
WO2011000518A1 (en) Pharmaceutical composition comprising desloratadine
EP0182569B1 (de) Anwendung von 1,6-Dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4H-pyrido[1,2-a]pyrimidin-3-carboxamid zur Vorbeugung und Behandlung von Gastrointestinalschäden
KR101199654B1 (ko) 안정한 서방출형의 경구 투여용 조성물
HK1010687B (en) Film coated tablet of paracetamol and domperidone

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)